Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Immunodeficiency and Autoimmune Disorders, and Acute Lymphoblastic Leukemia research.
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL
A noncoding mutation in the <i>NOTCH1</i> gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—2024 update
Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial
The NOTCH1 and miR-34a signaling network is affected by <i>TP53</i> alterations in CLL
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
Acquired <i>BTK</i> mutations associated with resistance to noncovalent BTK inhibitors
Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform
IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial
Profile of the Multicenter Cohort of the German Cancer Consortium’s Clinical Communication Platform
Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study
Molecular map of chronic lymphocytic leukemia and its impact on outcome
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma
<i>In Vivo</i> Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
Modeling the B‐cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors
Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial
NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted
Discovery of Candidate DNA Methylation Cancer Driver Genes
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax